Furthermore, we found that pyrimidine metabolic rate–limiting enzymes CAD, RRM2, DTYMK, TYMS, TK2, and NR5C2 were all associated with the clinical outcomes of lung cancer and liver cancer. Here, RRM2 is linked to lung carcinoma.